Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: A mechanistic explanation for ipilimumab-induced severe enterocolitis?
C REACTIVE PROTEIN;
CALGRANULIN;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
INFLIXIMAB;
IPILIMUMAB;
METHYLPREDNISOLONE;
TRANSCRIPTION FACTOR FOXP3;
ADULT;
BLOOD SAMPLING;
CANCER CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER SURGERY;
CASE REPORT;
CD3+ T LYMPHOCYTE;
CD4+ T LYMPHOCYTE;
CD8+ T LYMPHOCYTE;
COLONOSCOPY;
COMPUTER ASSISTED TOMOGRAPHY;
DRUG MECHANISM;
DRUG WITHDRAWAL;
HEPATITIS;
HUMAN;
HYPOPHYSITIS;
LETTER;
MALE;
MELANOMA;
PANCOLITIS;
PARENTERAL NUTRITION;
PRIORITY JOURNAL;
PROTEIN BLOOD LEVEL;
REGULATORY T LYMPHOCYTE;
STEROID THERAPY;
T CELL DEPLETION;
THORACIC MELANOMA;
THORAX CANCER;
THYROIDITIS;
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma
Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immunity. 2010; 10: 1-10.
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007; 30: 825-830.
Therapy with anti-TNFa antibody enhances number and function of Foxp3+ regulatory T cells in inflammatory bowel diseases
Boschetti G, Nancey S, Sardi F, et al. Therapy with anti-TNFa antibody enhances number and function of Foxp3+ regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis. 2011; 17: 160-170.
Peripheral regulatory T cells and serum transforming growth factor-β: Relationship with clinical response to infliximab in Crohn's disease
Di Sabatino A, Biancheri P, Piconese S, et al. Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2010; 16: 1891-1897.
Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab
Li Z, Arijs I, De Hertogh G, et al. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis. 2010; 16: 1299-1310.
Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis
Callahan MK, Yang A, Tandon S, et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J Clin Oncol. 2011; 29 (Abstract 2505).